NeuroPace, Inc. (NASDAQ:NPCE) Given Consensus Rating of “Moderate Buy” by Brokerages

NeuroPace, Inc. (NASDAQ:NPCE) has earned a consensus recommendation of “Moderate Buy” from the seven ratings firms that are presently covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is $14.00.

NPCE has been the topic of several research reports. Wells Fargo & Company dropped their price target on NeuroPace from $20.00 to $15.00 and set an “overweight” rating on the stock in a research report on Wednesday, August 14th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $18.00 price target on shares of NeuroPace in a report on Wednesday, August 14th. Finally, Morgan Stanley dropped their price objective on shares of NeuroPace from $9.50 to $8.00 and set an “equal weight” rating on the stock in a research note on Monday, July 15th.

Institutional Trading of NeuroPace

Several hedge funds have recently bought and sold shares of the company. Financial Advocates Investment Management lifted its position in NeuroPace by 50.0% in the 2nd quarter. Financial Advocates Investment Management now owns 15,000 shares of the company’s stock valued at $113,000 after purchasing an additional 5,000 shares during the last quarter. XTX Topco Ltd raised its position in shares of NeuroPace by 56.1% during the 2nd quarter. XTX Topco Ltd now owns 24,055 shares of the company’s stock worth $182,000 after buying an additional 8,643 shares in the last quarter. Hillsdale Investment Management Inc. bought a new stake in shares of NeuroPace during the 1st quarter worth about $155,000. Rhumbline Advisers bought a new stake in shares of NeuroPace during the 2nd quarter worth about $111,000. Finally, Acadian Asset Management LLC raised its position in shares of NeuroPace by 46.0% during the 2nd quarter. Acadian Asset Management LLC now owns 68,918 shares of the company’s stock worth $520,000 after buying an additional 21,703 shares in the last quarter. 78.83% of the stock is currently owned by institutional investors.

NeuroPace Trading Up 13.0 %

NPCE opened at $7.92 on Friday. NeuroPace has a 12-month low of $4.79 and a 12-month high of $18.15. The company has a debt-to-equity ratio of 4.05, a current ratio of 6.43 and a quick ratio of 5.56. The stock has a market capitalization of $227.84 million, a PE ratio of -6.66 and a beta of 1.80. The firm’s fifty day moving average price is $7.20 and its 200 day moving average price is $10.64.

NeuroPace (NASDAQ:NPCE) last posted its quarterly earnings results on Tuesday, August 13th. The company reported ($0.26) EPS for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.03. NeuroPace had a negative return on equity of 173.62% and a negative net margin of 45.61%. The business had revenue of $19.26 million during the quarter, compared to the consensus estimate of $18.30 million. During the same period last year, the firm earned ($0.36) earnings per share. The company’s revenue for the quarter was up 16.6% compared to the same quarter last year. As a group, research analysts expect that NeuroPace will post -1.14 EPS for the current fiscal year.

About NeuroPace

NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.